【摘要】 目的探讨肺癌患者凝血功能相关指标与临床病理特征及预后的相关性。方法对60例肺癌患者及20例健康人的血浆凝血酶原时间(PT)、纤维蛋白原(FIB)、部分活化凝血活酶时间(APTT)分别进行测定。结果肺癌患者血浆纤维蛋白原水平显著高于健康对照组(P<0.01),血浆PT、APTT值与对照组相比无显著性差异。肺癌组中除PT值在性别上有显著性差异外(P<0.05),其余各指标与患者的年龄、性别、病理类型、肿瘤大小、TNM分期、有无远处转移等临床病理特征之间无明显关系。血浆纤维蛋白原与生存期之间有显著的负相关(r=-0.32,P<0.01)。结论肺癌患者存在血浆纤维蛋白原水平增高,血浆纤维蛋白原水平与患者的生存期呈负相关,抗凝治疗对改善肺癌的预后可能有益。更多还原

【Abstract】 Objective To explore the relationship between coagulation markers level on pathophysiological characteristics and prognosis in patients with lung cancer.Methods The plasma levels of coagulation markers were detected in 60 patients with lung cancer and in 20 normal controls.Results The plasma level of fibrinogen in patients with lung cancer was significantly higher than those of the normal controls (P<0.01). There was no significant difference between the plasma levels of prothrombin time and active partial thromboplastin time and those of normal controls. The plasma level of prothrombin time in the patients with lung cancer showed significant difference in sex. The plasma levels of coagulation markers were not related to age, sex, histological classification, the size of the primary tumors, P-TNM stages, and distant metastasis. The plasma level of fibrinogen in the patients with lung cancer were negatively correlated to survival time (r=-0.32,P<0.01).Conclusion Elevation of plasma levels of fibrinogen exists in patients with lung cancer. The plasma level of fibrinogen is negatively correlated to the survival in patients with lung cancer. The anti-coagulability medicine treatment may be benefitial for the patients with lung cancer.更多还原